BMRN Q4 2017 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$358M+19.4% YoY

Gross Profit

$282M78.8% margin

Operating Income

$58M16.2% margin

Net Income

-$51M-14.3% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

-$25M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.8B

Stockholders' Equity

$2.8B

Cash & Equivalents

$598M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$358M	$300M	+19.4%
Gross Profit	$282M	$236M	+19.7%
Operating Income	$58M	-$90M	+164.8%
Net Income	-$51M	-$79M	+34.7%

Revenue Segments

Product One

$114M32%

Product Three

$107M30%

Product Two

$94M27%

Product Four

$28M8%

Product Six

$5M1%

Product Five

$5M1%

Geographic Segments

UNITED STATES

$163M46%

Europe

$73M20%

Rest Of World

$62M17%

Latin America

$61M17%